Glatiramer depot systems for treating progressive forms of multiple sclerosis
AssigneeMapi Pharma Ltd.
InventorsUri DANON, Nadav BLEICH KIMELMAN, Laura POPPER, Ehud MAROM
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating or ameliorating primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) and related symptoms by administering or implanting a depot formulation comprising glatiramer salts, such as glatiramer acetate (GA).
Claims20
A method of treating a patient diagnosed with primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS), the method comprising the step of administering or implanting a sustained release depot formulation comprising a therapeutically effective amount of a pharmaceutically acceptable salt of glatiramer to the patient.
A method of increasing the tolerability or convenience of glatiramer treatment, or increasing the adherence to glatiramer treatment, in a patient diagnosed with PPMS or SPMS and receiving an immediate-release or bolus glatiramer formulation, the method comprising reducing the frequency of glatiramer administration by administering a therapeutically effective depot formulation of a pharmaceutically acceptable salt of glatiramer to the patient, so as to thereby increase the tolerability, convenience or adherence of the patient to glatiramer treatment.
Dependencies are inferred from the claim text.